Graves Disease Market to Observe Impressive Growth During the Forecast Period (2023-2032), Evaluates DelveInsight | Novartis, AdvanceCor, Apitope, Worg Pharmaceuticals, AV7 Limited.
| Published date | 16 April 2024 |
M2 PRESSWIRE-April 16, 2024-: Graves Disease Market to Observe Impressive Growth During the Forecast Period (2023-2032), Evaluates DelveInsight | Novartis, AdvanceCor, Apitope, Worg Pharmaceuticals, AV7 Limited
(C)1994-2024 M2 COMMUNICATIONS
RDATE:16042024
The Graves Disease market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Graves Disease pipeline products will significantly revolutionize the Graves Disease market dynamics.
DelveInsight's "Graves Disease Market Insights, Epidemiology, and Market Forecast-2032'' report offers an in-depth understanding of the Graves Disease, historical and forecasted epidemiology as well as the Graves Disease market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Graves Disease market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
To Know in detail about the Graves Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Graves Disease Market Insights
Some of the key facts of the Graves Disease Market Report:
*The Graves Disease market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
*In August 2023, The investigational new drug (IND) application for TOUR006, developed by Tourmaline Bio, received clearance from the US Food and Drug Administration (FDA). This enables the commencement of a Phase IIb trial to evaluate TOUR006's efficacy in treating thyroid eye disease (TED), also known as Graves' ophthalmopathy. The study aims to compare the effects of TOUR006 at 20mg and 50mg doses with a placebo in patients with moderate to severe TED who are in the active phase of the disease.
*In January 2023, Immunovant Sciences GmbH has launched a study titled "A Phase 3, Multi-center, Randomized, Quadruple-masked, Placebo-controlled Study of Batoclimab for the Treatment of Participants With Active Thyroid Eye Disease (TED).
*According to the Graves' disease and thyroid foundation, Graves' disease, also known as toxic diffuse goiter, is the most common cause of hyperthyroidism - a disorder that...
To continue reading
Request your trial